KINDRED BIOSCIENCES, INC. (NASDAQ:KIN) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01
|
Entry into a Material Definitive Agreement.
|
Corden Pharma S.p.A, an Italian shared company (“Corden”),
entered into a Commercial Manufacture and Supply Agreement to which
Corden will provide certain manufacturing and supply services for
the Company’s proprietary product, ZimetaTM>(dipyrone
injection) (the “Manufacture and Supply Agreement”). The
Manufacture and Supply Agreement has an initial term of three years
and automatically extends for one additional period of two years
unless either party gives written notice to the other party of its
intention to terminate the agreement six months prior to the end of
the initial term. to the Manufacture and Supply Agreement, in
addition to manufacturing Zimeta, Corden will perform the quality
control and quality assurance testing, and batch review in
accordance with its standard operating procedures as well as
purchase and test all active material and components at Corden’s
expense. Both parties under the Manufacture and Supply Agreement
make certain representations and warranties regarding the
performance of their respective obligations and intellectual
property rights.
is not complete and is qualified in its entirety by reference to
the full text of Manufacture and Supply Agreement, a copy of which
is filed as Exhibit 10.1 to this Current Report portions of which
are subject to a FOIA confidential treatment request to the
Securities and Exchange Commission (the “SEC”) to Rule 24b-2
under the Securities Exchange Act of 1934, as amended.
Pharmaceuticals, Inc. (“SVP”) entered into a purchase agreement
(the “Purchase Agreement”) for the Company’s purchase of an
approximately 180,000 sq. ft. biologics plant with clean rooms,
utility, equipment, and related quality documentation suitable for
small molecule and biologics manufacturing (the Plant) that is
located in Elwood, Kansas. to the Purchase Agreement, subject to
the satisfaction of certain conditions described therein,
KindredBio shall pay a purchase price of $3,750,000 to purchase the
Plant, which includes approximately eight acres of land located at
1411 Oak Street, Elwood, Kansas, all improvements located at the
Plant, and all personal property and intangible property owned by
SVP and located at the Plant or used in connection with the
operation of the Plant. The Company expects to close within
30-days, subject to the completion of the diligence period and
satisfactions of the conditions of escrow.
and is qualified in its entirety by reference to the full text of
Purchase Agreement, a copy of which is filed as Exhibit 10.2 to
this Current Report and is incorporated by reference herein.
Company entering into the Manufacture and Supply Agreement and the
Purchase Agreement. The full text of the press release is filed as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.
|
Item 8.01
|
Other Events.
|
Issuance Sales Agreement (the “Sales Agreement”) with FBR Capital
Markets Co. (“FBR”) to which the Company offers and sells shares
of its common stock from time to time through FBR, acting as the
Companys distribution agent. to the Sales Agreement, FBR is
entitled to compensation at a commission rate equal to 3.0% of the
gross proceeds of sales of shares under the Sales Agreement. Offers
and sales of shares to the Sales Agreement are deemed to be an
at-the-market offering and are made to a Prospectus Supplement
(including an accompanying Prospectus) that covers the offer and
sale of shares with an aggregate offering price of up to
$30,000,000. The Company filed the Prospectus Supplement (and
accompanying Prospectus) with the SEC on December 19, 2016.
common stock with an aggregate offering price of $30,000,000 to the
Prospectus Supplement and the Sales Agreement. During the period
from April 1, 2017 through June 22, 2017, the Company sold
1,511,381 shares through FBR to the Prospectus Supplement and the
Sales Agreement and received approximately $10,653,639 in gross
proceeds. Net proceeds after deducting approximately $323,866 in
commissions were approximately $10,329,773. The Company has
summarized sales of shares to the Prospectus Supplement and the
Sales Agreement during the period prior to April 1, 2017 in its
most recent Annual Report on Form 10-K and Quarterly Report on Form
10-Q previously filed with the SEC.
|
Item 9.01
|
Financial Statements and Exhibits.
|
Exhibit No.
|
|
Description
|
|
10.1
|
|
Commercial Manufacture and Supply Agreement between
Kindred Biosciences, Inc. and Corden Pharma S.p.A dated June 21, 2017. |
|
10.2
|
|
Purchase Agreement between Kindred Biosciences, Inc. and
Strategic Veterinary Pharmaceuticals, Inc. dated June 21, 2017. |
|
99.1
|
|
Press Release of Kindred Biosciences, Inc. issued on June
26, 2017. |
Kindred Biosciences, Inc. ExhibitEX-10.1 2 kindred-zimetacommercialma.htm SUPPLY AGREEMENT Exhibit Exhibit 10.1TEXT MARKED BY [* * *] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.ZIMETA™ (DIPYRONE INJECTION) COMMERCIAL MANUFACTURE AND SUPPLY AGREEMENT June 21,…To view the full exhibit click here About KINDRED BIOSCIENCES, INC. (NASDAQ:KIN)
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company’s other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
